<DOC>
	<DOCNO>NCT01679028</DOCNO>
	<brief_summary>The purpose study see safe investigational new drug ( T89 ) well healthy Japanese subject tolerate give two single dos multiple dose .</brief_summary>
	<brief_title>Dose-Escalate Study Investigate Safety Tolerability T89 Japanese</brief_title>
	<detailed_description>This single centre , double-blind , randomize , placebo control , single- multiple- dose-escalation study . After informed consent obtain , subject evaluate medical history questionnaire , physical examination , blood urine collection clinical laboratory safety test , urine drug screen , serum pregnancy test woman , vital sign ECG . The subject fulfill inclusion criterion exclusion criterion provisionally enrol . For participation trial , subject instruct avoid prescription , over-the-counter ( OTC ) , alternative / complementary medication significant change diet without advance permission principal investigator . The subject instruct discontinue alcohol , caffeine bromine contain beverage/food . 20 subject enrol divide three Groups : Group A , Group B Group C .</detailed_description>
	<criteria>1 . Healthy male female volunteer age 2055 year . 2 . First generation Japanese , live U.S.A. le 5 year maintain Japanese lifestyle . 3 . The body mass index 18 30 kg/m2 . 4 . Willing take alcoholic beverage , caffeine brominecontaining beverage food ( e.g. , tea , coffee , chocolate , cola , etc . ) duration study begin screen visit . 5 . ECG clinically significant abnormality . 6 . No clinically significant medical history . 7 . Vital sign laboratory test clinically significant abnormality . 8 . Volunteers take medication would interfere procedure interpretation study data compromise subject safety within 4 week prior first dose , per principal investigator discretion . 9 . Volunteers must understand willing , able likely comply study procedure restriction . 10 . Volunteers must able give voluntary write informed consent . 1 . History uncontrolled , clinically significant neurologic , cardiovascular , haematological , pulmonary , hepatic , renal , metabolic , GI , urologic , immunologic , endocrine psychiatric disease . 2 . Pregnant nursing mother Women childbearing potential must negative pregnancy test , breast feeding establish method contraception investigator 's opinion acceptable . 3 . Have ongoing treatment medicine may interfere T89 administration similar medication within 2 week enter study , per principal investigator discretion . 4 . Blood donor recent 3 month . 5 . Have take part clinical trial involve administration study medication previous 1 month participation . 6 . Excessive alcohol use ( habitually consume 21 unit alcohol per week history alcohol abuse define DSMIVTR criterion ( unit alcohol equal 1 ounce hard liquor , 5 ounce wine 8 ounce beer within past two year ) . 7 . History evidence habitual use tobacco nicotine containing product within 3 month Screening , exception light smoking ( 5 cigarette per day equivalent ) 8 . Known hypersensitivity ingredient T89 relevant drug allergy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>T89 Safety Healthy Japanese population</keyword>
</DOC>